Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Kracie Poised to Re-Enter New Drug Biz with Scabies Treatment
August 29, 2014
- Chugai Provided 17.3 Billion Yen to Healthcare Professionals in 2013, Down 4% from 2012
August 29, 2014
- Sanofi Greater China Head Baschiera to Shepherd Japan Unit
August 29, 2014
- Roche Obtains First Refusal Right for All Chugai’s Products with Partial Amendment to Strategic Alliance Deal
August 29, 2014
- Canaglu to Hit Japan Market on Sept. 3: MTPC, Daiichi Sankyo
August 29, 2014
- Nippon Shinyaku Sets FY2018 Sales Target of 110 Billion Yen, Plans to Focus on Specialty Fields
August 28, 2014
- Novartis Japan Slapped with Warning over Travel Cost Payments for Doctors
August 28, 2014
- MTPC Aims at Over 17% Share for SGLT-2 Inhibitor Canaglu in Japan: Sales Division Head
August 28, 2014
- Otsuka Holdings Takes Aim at 915 Billion Yen Pharma Sales in FY2018 after Abilify Patent Loss
August 27, 2014
- Fixed-Dose Combination HIV Treatment Triumeq Approved in US: ViiV Healthcare
August 27, 2014
- AnGes MG Resumes Development of NF-κB Decoy Oligo Ointment Formulation for Atomic Dermatitis
August 26, 2014
- Chugai to Restrict Use of Alecensa to Medical Institutions, Doctors that Meet Specified Conditions
August 26, 2014
- AnGes MG Revamps US Unit to Prepare for Global PIII Study of Collategene
August 25, 2014
- Janssen Files Anti-HIV Combination Tablet for Approval
August 25, 2014
- Latuda Goes on Sale in UK: Sumitomo Dainippon
August 25, 2014
- Pfizer Japan to Create New Unit for its Innovative Drug Business in December
August 22, 2014
- Nichi-Iko to Launch Own Products in Thailand in October
August 22, 2014
- Carfilzomib Monotherapy Fails to Meet Primary Endpoint in PIII: Amgen, Onyx
August 22, 2014
- MTPC, AZ Ink Research Collaboration Deal in Diabetic Nephropathy
August 21, 2014
- Eisai Files Fycompa for Primary Generalized Tonic-Clonic Seizures in US, Europe
August 21, 2014
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…